As early-stage life sciences companies prepare for their next financing or partnership, intellectual property due diligence is often the first, and most consequential, checkpoint.

Why do some life sciences companies stall between Series B and IPO?

J.P.Morgan Asset & Wealth Management, one of the largest global investment managers, has announced it will stop using third‑party proxy advisory firms for U.S. proxy voting and will instead rely on a newly launched internal, AI‑powered platform, Proxy IQ, to manage all aspects of the voting process for more than 3,000 company annual meetings.

Transitioning from discovery to clinical development marks a defining moment for emerging biotech companies. It’s also a time to consider evolving your IP strategy from protecting ideas to protecting assets.